{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-26-000032","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-05-13T11:00:44+00:00","discovered_at":"2026-05-13T11:05:00.322441+00:00","generated_at":"2026-05-13T11:15:50.174790+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Avalo reports Q1 net loss $19.6M, Phase 2 HS trial meets endpoints, $431M offering","bullets":["Phase 2 LOTUS topline: HiSCR75 absolute improvement 42.2% (150mg) and 42.9% (300mg) vs placebo 25.6%; p=0.018 and 0.015.","Q1 2026 net loss $19.6M ($0.98 loss/share) vs $13.1M prior year, driven by higher R&D costs.","Cash $82.0M as of Mar 31, 2026; subsequent public offering raised gross $431.3M (net $405M), extending runway into 2029.","Milestone Buyout Option: paid $2.25M for option to replace $15M milestone with $5.125M payment upon Phase 3 start.","R&D expense $14.0M (+$4.9M YoY); G&A $6.9M (+$1.3M YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-26-000032","json":"https://secwatch.observer/filing/0001534120-26-000032.json","markdown":"https://secwatch.observer/filing/0001534120-26-000032.md","text":"https://secwatch.observer/filing/0001534120-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/0001534120-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/avtx-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:15:50.174790+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d81e60ea3dbeba6c96ea8b38f15a11d1e780bade","claim":"Avalo Therapeutics, Inc. reported first quarter 2026 results: net income Net loss was $19.6 million, EPS Basic and diluted net loss per share was $0.98.","evidence_excerpt":"On May 13, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/0001534120-26-000032-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Net income","value":"Net loss was $19.6 million"},{"label":"EPS","value":"Basic and diluted net loss per share was $0.98"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}